神經內分泌腫瘤治療市場：分析與預測（2022-2028）

全球神經內分泌腫瘤治療市場規模預計在預測期內增長約 10%。

神經內分泌腫瘤 (NET) 病例數量的增加預計將在預測期內加速對各種治療方案的需求。 隨著新的診斷和治療方法的發展，該領域正在迅速發展。 高需求的 NET 治療市場主要是由射頻消融和 Ga 標記的放射性核甘酸治療等檢測方法的持續研發工作推動的。

按地區劃分，北美市場處於領先地位。 這主要得益於發達的醫療基礎設施和眾多的醫務工作者。 此外，該地區胃神經內分泌腫瘤、肺神經內分泌腫瘤、胰腺神經內分泌腫瘤和類癌數量的增加也推動了市場增長。

本報告調查全球神經內分泌腫瘤治療市場，定義和概述市場，分析影響市場增長的各種因素、市場規模的變化和預測，以及按各個細分市場/地區/主要國家細分、供需趨勢，競爭環境，主要公司概況等。

內容

第一章介紹

第二章調查方法及前提條件

第 3 章市場概述

第 4 章執行摘要

第 5 章 COVID-19：對神經內分泌腫瘤治療市場的影響

第 6 章神經內分泌腫瘤治療市場：收益趨勢和預測

第 7 章市場洞察：按產品分類

• 生長抑素類似物 (SSA)
• 靶向治療
• 化療
• 其他

第 8 章市場洞察：按指示

• 肺
• 胰腺
• 胃腸道
• 其他

第 9 章市場洞察：最終用戶

• 醫院
• 醫務室
• 其他

第 10 章市場洞察：按地區

• 北美
• 歐洲
• 亞太地區
• 其他地區

第 11 章神經內分泌腫瘤治療市場：市場動態

• 市場驅動力
• 市場問題
• 影響分析

第 12 章神經內分泌腫瘤治療市場：市場機會

第 13 章神經內分泌腫瘤治療市場：市場趨勢

第14章需求側與供給側分析

• 需求方分析
• 供應方分析

第 15 章價值鏈分析

第 16 章衝突場景

第十七章公司簡介

• Pfizer Inc.
• Novartis AG
• Chiasma Inc.
• Ipsen
• Abbvie Inc.
• Valeant Pharmaceuticals International Inc.
• Jubilant Life Sciences Ltd.
• Teva Pharmaceutical Industries Ltd
• F. Hoffmann-La Roche Ltd
• Advanced Accelerator Applications

第18章 免責事項

The global neuroendocrine tumor treatment market is expected to grow at a significant rate of around 10% during the forecast period. Over the course of the forecast period, an increase in the number of cases of neuroendocrine tumors (NETs) is anticipated to accelerate the demand for various treatment options. As new diagnostics and therapies are developed, this is a rapidly developing field. The demand NET treatment market is primarily driven by ongoing R&D efforts in detection methods like radiofrequency ablation and Ga-labeled radionucleotide therapies.

For instance, Progenics Pharmaceuticals, Inc.'s PSMA Targeted PET Imaging Agent, for instance, is currently in the clinical trial phase and is anticipated to aid in the treatment of prostate cancer. Another important factor driving the expansion of the NET market is the substantial investment in the field made by cancer research organizations and governments worldwide.

Pfizer Inc., Novartis AG, Chiasma Inc., Ipsen, Abbvie Inc., Valeant Pharmaceuticals International Inc., Jubilant Life Sciences Ltd., Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd., and Advanced Accelerator Applications. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst indication, gastrointestinal category to witness robust CAGR during the forecast period"

Based on type, the market is segmented into lungs, pancreas, gastrointestinal, and others. Among them, the gastrointestinal category is to witness the highest CAGR during the forecast period owing to the more number of patients seen for gastric neuroendocrine growths so there is developing prominence and driving this segment.

Moreover, the pancreas portion is supposed to have consistent development during the following couple of years. The expansion of the market is anticipated to be aided by an increase in R&D expenditures for the creation of novel therapies for pancreatic NETs.Pfizer Inc.'s SUNITINIB is being tested in a phase III clinical trial for the treatment of NETs in the pancreas.

"Amongst end-user, the hospitals to hold a significant share in the market in 2020"

On the basis of drive type, the market is categorized into hospitals, clinics, and others. Among these, the hospitals category to hold a significant share of the market in 2020. This is mainly due to these facilities being used for a lot of diagnostic procedures, a large number of patients treated at hospitals, and the availability of trained professionals. The segment's expansion is anticipated to be further bolstered by the availability of numerous NET diagnosis options and developed technologies.

"North America to hold a significant share in the market"

For a better understanding of the market adoption of the cardiac monitoring industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America); Europe (Germany, United Kingdom, France, Spain, Italy, Rest of Europe); Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific); and the Rest of World. North American region helped the region to obtain a dominating position in the market. This is mainly due to the well-settled healthcare infrastructure, and availability of medical professionals. Furthermore, rising cases of gastric neuroendocrine tumors, lung neuroendocrine tumors, pancreatic neuroendocrine tumors, and carcinoid tumors in the region are the propel the growth of the market. For instance, carcinoid tumor affects between 3,000 and 30,000 people in the United States, according to data updated in 2021 by the National Center for Advancing Translational Sciences Genetic and Rare Diseases Information Center. These tumors typically originate in the gastrointestinal tract or the lungs. It is anticipated that the market will expand as a result of the widespread incidence of neuroendocrine cancer in the region.  

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

The global neuroendocrine tumor treatment market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Neuroendocrine Tumor Treatment Market
• 2.2. Research Methodology of the Neuroendocrine Tumor Treatment Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE NEUROENDOCRINE TUMOR TREATMENT MARKET

6 NEUROENDOCRINE TUMOR TREATMENT MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY PRODUCTS

• 7.1. Somatostatin Analogs (SSAs)
• 7.2. Targeted Therapy
• 7.3. Chemotherapy
• 7.4. Others

8 MARKET INSIGHTS BY INDICATION

• 8.1. Lungs
• 8.2. Pancreas
• 8.3. Gastrointestinal
• 8.4. Others

9 MARKET INSIGHTS BY END USER

• 9.1. Hospitals
• 9.2. Clinics
• 9.3. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 NEUROENDOCRINE TUMOR TREATMENT MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 NEUROENDOCRINE TUMOR TREATMENT MARKET OPPORTUNITIES

13 NEUROENDOCRINE TUMOR TREATMENT MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

• 16.1. Competitive Landscape
  • 16.1.1. Porters Fiver Forces Analysis

17 COMPANY PROFILED

• 17.1. Pfizer Inc.
• 17.2. Novartis AG
• 17.3. Chiasma Inc.
• 17.4. Ipsen
• 17.5. Abbvie Inc.
• 17.6. Valeant Pharmaceuticals International Inc.
• 17.7. Jubilant Life Sciences Ltd.
• 17.8. Teva Pharmaceutical Industries Ltd
• 17.9. F. Hoffmann-La Roche Ltd
• 17.10. Advanced Accelerator Applications

18 DISCLAIMER